In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

Boston-based biotechnology firm developing therapy for treatment of gastrointestinal stromal tumors - Anadolu Ajansı ...

Luke Miels, GSK’s chief commercial officer, stated that the acquisition is consistent with the company’s strategy of acquiring assets targeting validated medical needs, even in areas where ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

ST Germain D J Co. Inc. increased its stake in GSK plc (NYSE:GSK – Free Report) by 195.5% during the fourth quarter, ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

GSK (GSK) stock is in focus as the company is nearing a $1B deal to acquire IDRx, a private biotech focused on a rare ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...